{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AVNS",
  "name": "Avanos Medical, Inc.",
  "url": "https://orbyd.app/dossiers/AVNS/",
  "json_url": "https://orbyd.app/dossiers/AVNS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Take-private is done: AVNS holders approved the $25.00/share all-cash AIP buyout on 2026-07-22 (~99.75% of votes cast), all regulatory clearances in hand, close guided by 2026-07-27 with NYSE delisting on completion. Price is pinned to cash; no narrative to trade, only a near-nil last-session bust tail before the equity disappears.",
  "invalidation_trigger": "A daily close below $22.50 — a >10% break of the $25.00 cash floor — would signal a last-minute completion failure (waiver/MAE scare, though regulators cleared 2026-07-02 and the vote passed 2026-07-22) and reopen a standalone trade toward the ~$14.53 pre-deal zone; a competing bid above $25.00 pre-close would do the same to the upside.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Vote passed 2026-07-22: ~99.75% of votes cast in favor, ~74.96% of shares outstanding; all regulatory approvals received 2026-07-02.",
    "Close guided no later than 2026-07-27; on completion AVNS delists from NYSE — no US-listed equity to trade after that.",
    "S&P SmallCap 600: V2X replaces AVNS effective before open Monday 2026-07-27 (announced 2026-07-20) — index-committee confirmation the deletion is locked.",
    "Deal terms (2026-04-14 PR + 8-K): $25.00/sh cash, $1.272B EV, 72.1% premium to 2026-04-13 close (~$14.53), unanimous board approval, explicitly NO financing condition.",
    "AIP is a PE financial sponsor, not a strategic — base rate of a topping bid at this stage is near nil.",
    "Q1 print 2026-05-05 (Adj EPS $0.22 vs $0.14; sales $182.2M vs $170M) is healthy — caps break downside but is moot to a pinned, delisting price.",
    "Benzinga RSI-90 'may collapse' screens (2026-05-04) are artifacts of the 2026-04-14 ~69% deal gap, not momentum — a cash-floored stock does not mean-revert off oscillators.",
    "This dossier goes dead on delisting (~2026-07-27) — retire from active watchlist after close confirmation."
  ],
  "body_markdown": "\n## Current Thesis\nThe take-private is effectively closed. On 2026-07-22 Avanos stockholders approved the all-cash acquisition by American Industrial Partners (AIP) at **$25.00/share**, with roughly **99.75% of votes cast** in favor (about 74.96% of shares outstanding). All required regulatory clearances were received 2026-07-02, and both parties guide completion **no later than 2026-07-27**, at which point the common stock delists from the NYSE. The independent confirmation is index-mechanical: S&P announced 2026-07-20 that **V2X replaces AVNS in the S&P SmallCap 600 effective before the open on Monday 2026-07-27** — committees only pull a name when a deletion is locked. For a narrative-momentum mandate there is nothing here: price is contractually pinned to the cash number, the residual discount is a few days of arb yield, and the security disappears at close. No leg to buy, no trend to ride, no catalyst that pays beta.\n\n## Bull Case\n- **Deal risk is essentially retired.** Regulatory approvals in hand as of 2026-07-02; shareholder approval delivered 2026-07-22 at ~99.75% of votes cast — the two most common arb-killers (financing, then vote) are both cleared.\n- **No financing condition.** The 2026-04-14 terms fund the $25.00 cash via an AIP equity commitment (EV **$1.272B**, a 72.1% premium to the 2026-04-13 close of ~$14.53); there was never a lender out to fail.\n- **Standalone business is healthy, capping any break downside.** Q1 print (2026-05-05): Adj EPS **$0.22 vs $0.14** consensus, sales **$182.2M vs $170M** — a collapsed deal would land on improving fundamentals rather than a distressed base.\n- **The only \"bull\" left is arb yield to a dated close.** With completion guided by 2026-07-27, duration is measured in days — a return this book does not harvest.\n\n## Bear Case\n- **There is no momentum trade and no equity to trade after Monday.** Narrative velocity, multiple expansion and upside beta are all zero;\n- **The residual tail is asymmetric to the downside.** A last-session bust — improbable now that the vote is counted and regulators are cleared — re-rates toward the pre-deal ~$14.53 zone, a 40%+ air pocket from the $25.00 pin even on a clean Q1.\n- **A financial sponsor removes topping-bid optionality.** AIP is private equity, not a strategic with synergies; with the vote done and delisting scheduled, a superior proposal at this stage is a near-nil base rate.\n- **\"Overbought\" screens on this name are artifacts.** Benzinga's RSI-90 flag (2026-05-04, \"may collapse this month\") is the residue of the 2026-04-14 ~69% deal gap, not distribution — a cash-clamped price does not reprice off momentum oscillators.\n\n## Setup & Price Structure\nShares gapped from the ~$14.53 close (2026-04-13) into the low-$24s on the 2026-04-14 announcement and have held a tight band just beneath the **$25.00** consideration ever since, with the discount compressing toward zero as the 2026-07-22 vote and ~2026-07-27 close arrived. Announcement-day volume spiked, then bled back to arb-desk baseline. Moving averages, EMAs, breakout shelves and RSI carry no signal on a price set by contract; the only chart event that would matter is a discrete gap *below* the band, which would mean the tape is pricing a break rather than a completion. Absent that, there is no trend, no support test, and no parabola — just a spread grinding into settlement, followed by delisting.\n\n## Catalyst Calendar (next 30 days)\n\n*No upcoming dated catalysts on file — the dated entries below have passed.*\n\n## Elapsed catalysts\n\n- **~2026-07-27 (guided) — merger completion & NYSE delisting.** Both parties guide close no later than this date; on completion holders receive $25.00 cash and the stock stops trading. *(passed 13d ago)*\n- **2026-07-27 (confirmed) — S&P SmallCap 600 removal effective before the open.** V2X replaces AVNS (announced 2026-07-20); forced index-fund selling clears mechanically into the close. *(passed 13d ago)*\n- **Vote already counted — 2026-07-22 special meeting (ELAPSED).** Approved at ~99.75% of votes cast; no further shareholder gate remains. *(passed 18d ago)*\n- No earnings, guidance, or standalone company catalyst is scheduled — the Q1 print (2026-05-05) is the last operating datapoint and is moot to a pinned price. *(passed 96d ago)*\n\n## What Would Change Our Mind\nThe dormant read reopens only on evidence the deal fails to settle: a **daily close below $22.50** — a >10% break of the $25.00 cash floor — would signal a last-minute completion problem (a waiver dispute or MAE scare, though regulators cleared 2026-07-02 and the vote passed 2026-07-22) and reintroduce a modelable standalone trade back toward the ~$14.53 pre-deal zone. Symmetrically, an improbable competing proposal printing **above $25.00** before close would reopen the name to the upside. Neither is the base case; the base case is settlement on/around 2026-07-27 and delisting, after which there is no US-listed equity to analyze.\n\n## Correlation Notes\nAVNS trades on deal mechanics, not sector beta — its correlation to medtech peers, small-cap indices (its own S&P 600 membership ends 2026-07-27) and rate-sensitive healthcare baskets has been near zero since the 2026-04-14 gap. The only meaningful covariate is deal-completion risk itself, which is idiosyncratic and now largely resolved. As a data point for the special-situations sleeve, it reads as a clean go-private that never developed a bust-or-bump edge: financial sponsor, no financing condition, fast regulatory path, overwhelming vote. It is a template for why fixed-price cash arb is not a narrative-momentum instrument, not a name to redeploy into.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-07-26T11:49:05+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}